SUNNYVALE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Lemonaid Health, Inc., a subsidiary of 23andMe Holding Co., (Nasdaq: ME), and a leading telemedicine provider, is now offering Petros...
NEW YORK, NY / ACCESSWIRE / September 8, 2022 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a leading provider of therapeutics for men's health, today announces newly published third party data in the International Journal of UrologyEfficacy and safety of avanafil as compared with sildenafil in the treatment of erectile dysfunction by Kumar, Pathade, Gupta, Goyal, Rath, Thakre, Sanmukhani, and Mittal, detailing the Company's PDE 5 inhibitor STENDRA® (avanafil) tablets in a non-inferiority, head-to-head study compared to sildenafil (Viagra) which was conducted in India. The primary efficacy endpoint was improvement in erectile function based on domain score of the International Index of Erectile Function (IIEF). Some secondary endpoints included, the percentage of patients reaching a normal IIEF-EF score; percentage of successful vaginal penetrations and successful intercourse in the two groups; and percentage of doses with some erection in 15 mins in the two groups. The Zydus Healthcare-sponsored study, also showed rapid onset of action of STENDRA as demonstrated by a questionnaire determining whether some erection occurred within 15 minutes of dosing (see important safety information below).
NEW YORK, July 28, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men’s health, today confirmed that a press release issued on July 28, 2022 regarding a purported acquisition of the company was fraudulent and not issued by the Company. The Company is not a party to any such acquisition and has reported the fraudulent activity to Nasdaq.
NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (“Petros” or “the Company”) (Nasdaq: PTPI), a leading provider of therapeutics for men’s health, today announced financial...
Petros Pharmaceuticals has decided on the way forward for its topical treatment of a connective tissue disorder of the penis. After talking to the FDA, Petros plans to follow the 505(b)(2) pathway, enabling it to leverage data on approved drug products to support its application.
NEW YORK, May 03, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men’s health, announces today they will be pursuing the 505(b)(2)...
NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men’s health, announces today that President and Chief Commercial...
NEW YORK, April 26, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (Petros, Nasdaq: PTPI), a leading provider of therapeutics for men’s health, today announces it has entered into a Sponsored Research Agreement (SRA) and an Option Agreement with the Wellman Center of Massachusetts General Hospital (“Mass General”), an affiliate of Harvard Medical School. Under the agreement, researchers will evaluate incorporating the use of a tissue-specific oxygenation sensor with the goal of monitoring and understanding the success of Erectile Device Therapy. Accompanying the Sponsored Research Agreement, Petros will enter into an Agreement for an option to negotiate an exclusive license of the tissue-specific oxygenation sensor within specific human tissues. The Company plans to apply the technology to potentially enhance its existing erectile device therapy.
NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (“Petros” or “the Company”) (Nasdaq: PTPI), a leading provider of therapeutics for men’s health, today provides positive...
NEW YORK, April 01, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (“Petros” or “the Company”) (Nasdaq: PTPI), a leading provider of therapeutics for men’s health, today announces financial...